Immuno-oncology
Conference Coverage
Armored CAR protects T cells, induces remissions
SAN DIEGO – A CAR T-cell construct engineered to enhance T-cell persistence and immune function induced high complete remission rates in a phase 1...
Latest News
Severe adverse events seen in placebo arm of cancer clinical trials
A significant number of patients treated only with placebo during cancer clinical trials still report serious adverse events.
Conference Coverage
PD-L1 expression best predicts response to atezolizumab + nab-paclitaxel for mTNBC
SAN ANTONIO – IMpassion130 analyses show that PD-L1 expression on tumor-infiltrating immune cells is the best...
From the Journals
Age-related gene expression may affect responses to RCC therapy
Older patients with ccRCC may respond better than younger patients to phosphoinositide 3-kinase (PI3K) or checkpoint inhibition because of age-...
Video
JULIET: CAR T cells go the distance in r/r DLBCL
SAN DIEGO – Median overall survival among patients with complete responses to CAR-T cell therapy in the JULIET trial has not been reached.
Video
Gut bacteria influence HCT outcomes
SAN DIEGO – Gut microbiome diversity predicts overall survival after hematopoietic cell transplant.
Conference Coverage
A novel tracer shows promise for detecting CD8 T-cells in advanced solid tumors
WASHINGTON – PET with 89Zr-IAB22M2C provides detailed information on CD8 T-cell biodistribution in patients with advanced solid tumors...
Conference Coverage
Lenvatinib/Pembrolizumab shows promise in previously treated metastatic NSCLC
WASHINGTON – Interim findings from a phase 1b/2 study indicate the combination shows promising clinical activity and...
Conference Coverage
TMB measured by NGS may ID SCLC patients who will benefit from immunotherapy
WASHINGTON – Targeted next-generation sequencing may help identify SCLC patients likely to benefit from...
Conference Coverage
Monalizumab-cetuximab combo shows promise in advanced head and neck SCC
WASHINGTON – Combined monalizumab + cetuximab is safe and promotes deep, durable responses in recurrent or...
Conference Coverage
Immunotherapy-related toxicities may be more common than reported in trials
SAN DIEGO – Certain immune-related adverse events related to PD1/PD-L1 treatment of patients with non–small cell...